U.S. Chamber comments on the Centers for Medicare & Medicaid Services' ("CMS's") Draft Guidance implementing Initial Price Applicability Year 2028 ("IPAY 2028") of the Medicare Drug Price Negotiation Program created by the Biden Administration under the Inflation Reduction Act ("IRA").
Recommended
- Intellectual Property
The Obesity Cure We've Been Waiting for Is Here. Policymakers Shouldn't Kill It.
GLP-1 medicines are transforming obesity care, but price controls could undermine innovation, access, and future cures.
By Brad Watts
- Intellectual Property
The Global Fight for IP Protection Is Changing Fast
By Kelly Anderson
View this online




